Japanese generics maker eyes Kyorin buyout

Sawai Pharmaceutical (4555.T), one of Japan's top makers of generic drugs, has bought almost five percent of Kyorin (4569.T) and wants to turn the mid-sized drugmaker into a wholly owned unit through a tender offer, the Nikkei reported. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.